首页> 外文期刊>European journal of human genetics: EJHG >Genetic testing and common disorders in a public health framework Recommendations of the European Society of Human Genetics
【24h】

Genetic testing and common disorders in a public health framework Recommendations of the European Society of Human Genetics

机译:公共卫生框架中的基因检测和常见疾病欧洲人类遗传学会的建议

获取原文
获取原文并翻译 | 示例
           

摘要

INTRODUCTIONIn recent years, the attention of the genomics and genetics research community has shifted toward understanding the basis of common disorders. The spectacular growth of genome-wide association studies has shed new light on the variants influencing risk factors. Understanding pathogenesis and etiology, and finding new ways to prevent and treat those diseases are major challenges. In the era of genomics, a promise of personalized prevention and drug treatment is presented, which many people meet with enthusiasm but which others call into question. The Public and Professional Policy Committee (PPPC) of the European Society of Human Genetics (ESHG), EuroGentest and the Institute for Prospective Technological Studies (IPTS) convened to discuss the relevance and possibilities of genetic testing for common disorders. Currently (in 2010), the genetics research community is skeptical about the possibilities of genetic susceptibility testing and screening contributing significantly to the improvement of the quality of health care. Meanwhile, some applications of very limited clinical utility have become available directly to consumers. Recently, the PPPC published critical recommendations on policy concerning DTC genetic testing (EJHG, 25 August 2010). When considering the potential of new genomic developments for a public health perspective, this Background Document takes the spectrum ranging from monogenic disorders on the one hand to common complex disorders on the other hand into account. It is argued that associations between genetic variants and disease risks of clinical relevance have been established, for instance for hereditary breast and ovarian cancer, colon cancer, diabetes mellitus (MODY subtypes), thrombosis, cardiovascular disorders, celiac disease and Alzheimer's disease. Although these examples relate to the monogenic subforms of common disease, they can nevertheless be used to reflect on the possibilities and relevant obstacles in using the ne...
机译:引言近年来,基因组学和遗传学研究界已将注意力转向了了解常见疾病的基础。全基因组关联研究的惊人增长为影响风险因素的变异提供了新的思路。了解发病机理和病因,并找到预防和治疗这些疾病的新方法是主要挑战。在基因组学时代,提出了个性化预防和药物治疗的希望,许多人对此充满热情,但其他人对此表示怀疑。欧洲人类遗传学会(ESHG),EuroGentest和前瞻性技术研究所(IPTS)的公共和专业政策委员会(PPPC)召开会议,讨论了常见疾病的基因检测的相关性和可能性。目前(2010年),遗传学研究界对遗传敏感性测试和筛查对改善医疗质量做出重大贡献的可能性表示怀疑。同时,临床实用性非常有限的一些应用已直接提供给消费者。最近,PPPC发布了有关DTC基因测试政策的重要建议(EJHG,2010年8月25日)。从公共卫生的角度考虑新基因组开发的潜力时,本背景文件考虑了从一方面的单基因疾病到另一方面的常见复杂疾病的范围。据认为,遗传变异与临床相关疾病风险之间已建立关联,例如遗传性乳腺癌和卵巢癌,结肠癌,糖尿病(MODY亚型),血栓形成,心血管疾病,腹腔疾病和阿尔茨海默氏病。尽管这些例子与常见疾病的单基因亚型有关,但仍可以用来反思使用新基因的可能性和相关障碍。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号